Sent to FFUP 9 23, 2018. Writer Long Time FFUP Friend, Needs to Remain Anonymous

Total Page:16

File Type:pdf, Size:1020Kb

Sent to FFUP 9 23, 2018. Writer Long Time FFUP Friend, Needs to Remain Anonymous Sent to FFUP 9 23, 2018. Writer long time FFUP friend, needs to remain anonymous 1) Notice of suicide Suicide at Stanley “Something Occurred I think you should know about. A prisoner committed suicide in Stanley on Fri. Sept 21st. That in itself is not uncommon but the circumstances indicate tht it shouldn’t have happened. Most of my information is second hand so it needs to be verified The guy is allegedly someone named Koch, a person who looked like he was in his 20/s ( actually he looked about 16 but I think he was in his 20’s), If it was Koch, then he was on some sort of medication since he was a juvenile. When he arrived at Stanley they discontinued his medication. He had been up to the library several times asking for help and had made numerous requests to HIS staff to give him back the medications but they refused. I think that’s what drove him to kill himself. Within a couple of hours of finding his body, they cleared his personal property out of his cell and made his cell mate go back into the cell. I would have thought they would leave the cell empty for awhile after an incident like that. I think somebody should alert the news media, senator Taylor and tony Evers, I am going to see the parole commission in October and If my name comes up about this incident I know they will retaliate, against me by giving me a long defer. That’s why I am telling you, not speaking out myself. I spoke to Koch in the library about his problem with them discontinuing his meds. I know that much to be true. But whether he is the one who killed himself is second hand knowledge which is why the above named parties should be notified and given the secondhand information so they can verify whether it is true. If it is true, I expect the DOC to institute cover-up about his pleas to reinstate his medication. The denial of which most likely led to his suicide. I’ll leave this up to you to proceed on this matter however you feel fit. “ sent 9 23 18 2) Below is response from prisoner litigator on Koch’s withdrawal of meds. He goes through history of the DOC cutting off this medication- and he did a lawsuit on it- what the DOC did was illegal. Reed Richardson, SCI Warden Cathy Jesse. Secretary WI DOC September 19,2018 Re: Abrupt withdrawal of Meds for Ian Koch #448308, SCI Hello, I just read a letter by Ian Koch who is in a crisis situation. He is not having any success in getting help and I am writing to make sure his requests for help get to you. Upon transfer to SCI he was abruptly taken off his meds- Klonopin. He has been having serious side effects for over 60 days and has repeatedly asked for help which has been denied to the point that he was threatened with a conduct report if he complained again. This guy is in panic and I quickly googled “side effects with abrupt withdrawal from klonopin” and there are pages of sites on this replete with warnings not to do it- that withdrawal must be done slowly and carefully. I know well about the general scare and caution about using addictive drugs and suppose this is an overreaction to that by your staff. What has been done in Ian’s case is brutal and dangerous, however. If withdrawal is chosen, it must be done with real care. I also know how short of staff the entire DOC is; however there is no excuse for the treatment Ian has received. I ask you to look into this matter and see that Ian is given good care . and his progress is monitored whether he is kept off this drug or its use is reinstated. There is so much literature on how to handle Klonopin, please ask your staff to educate themselves on the subject. I am enclosing Ian’s letter to me and one of the results of the google search I did. I thank you for your attention. Peg Swan 29631 Wild Rose Drive Blue River, WI 53518 Clonazepam Withdrawal Symptoms, Length, and Treatment Learn If Detox Is Needed Content Overview What Are Some Clonazepam Withdrawal Symptoms? Clonazepam withdrawal symptoms can include: Headaches Fatigue Stomach pain Confusion Nausea Anxiety Tremors Depression Sweating Seizures Hallucinations Thoughts of suicide Dizziness Acute withdrawal symptoms peak two weeks after stopping use of clonazepam, but subtle signs can last anywhere from a week to a month. Find Fast Benzodiazepines are a class of drugs that act as central nervous system depressants, or sedatives and tranquilizers. Clonazepam, with a trade name of Klonopin, is an anxiolytic drug prescribed to manage seizure disorders and also panic disorders by slowing down some of the bodily and brain functions related to anxiety and stress. Clonazepam is thought to increase the presence of gamma amino-butyric acid (GABA) in the brain, which helps to slow down heart rate and blood pressure, and calm emotional disturbances. The U.S. Food and Drug Administration, or FDA, warns that taking Klonopin can be habit-forming and that users may become physically and psychologically dependent to the drug. Users should therefore not stop taking clonazepam suddenly without medical supervision due to the dangerous side effects, or withdrawal symptoms that may occur after the discontinuation of the drug. Side effects and withdrawal may occur in users who take the drug only as prescribed. Klonopin and other benzodiazepines are commonly abused and even taken with other drugs and/or alcohol, which may increase the withdrawal side effects. The Drug Abuse Warning Network (DAWN) reported that over 61,000 people sought emergency department treatment for a negative reaction involving the recreational, or nonmedical use, of clonazepam in 2011. Clonazepam, when taken or abused for any length of time, can create chemical changes in the brain. Parts of the brain that are normally suppressed by the drug may become accustomed to the interaction of the drug and stop performing normally without it. This is when a dependence on the drug has been formed. When clonazepam is then removed, these functions that were being dampened are suddenly not, and a kind of rebound may occur. The symptoms that Klonopin may have been managing, such as anxiety, panic, seizures, and insomnia, may then be magnified. Withdrawal Symptoms Withdrawal from clonazepam can be dangerous and even potentially life-threatening. The drug should not be stopped suddenly or without the direct supervision and guidance of a medical professional. Potentially fatal seizures or a coma may occur with the sudden cessation of Klonopin. Catatonia is also a rare, but documented, side effect of clonazepam withdrawal, as reported by the journal Psychosomatics. Vital signs such as blood pressure, heart rate, respiration levels, and body temperature may need to be monitored during withdrawal, as they can jump to unhealthy levels rather quickly as the brain and body attempt to restore order without clonazepam. Physical symptoms of clonazepam withdrawal may Increased blood pressure include: Impaired respiration Headache Dizziness Stomach pain Blurred vision Nausea and vomiting Fatigue Tremors Muscle spasms and cramps Short-term memory loss Impaired coordination and motor functions Insomnia Diarrhea Irregular heart rate or heart palpitations Feeling lightheaded Sweating Seizures Benzodiazepine withdrawal is also known for the debilitating psychological side effects that may occur after a drug such as clonazepam is stopped. Perhaps one of the most serious emotional side effects of Klonopin usage is the increased risk for suicidal thoughts and behaviors, as the FDA even made a point to add warnings about the potential for increased suicidal ideation to Klonopin labels in 2009. Psychological symptoms of withdrawal from clonazepam may also include: Hallucinations Anxiety Nightmares Panic Mental confusion Depression Short-term memory lapses Drug cravings Difficulties concentrating Lack of motivation Irritability Feeling “out of it” and disconnected from reality Drastic mood swings Anger and hostility Trouble feeling pleasure The emotional benzodiazepine withdrawal symptoms will usually subside with time and psychological support. Benzo Withdrawal Phases Things Influencing Withdrawal There are generally three main phases of benzodiazepine withdrawal: early withdrawal, acute withdrawal, and protracted, or late withdrawal. Since Klonopin is a benzo with a long half-life of 18-50 hours, as published by the journal Case Reports in Psychiatry, withdrawal will not usually start until about 1-3 days after the last dose, or when the drug stops being effective. Early withdrawal usually lasts about 2-4 days and is likely to include “rebound” symptoms, such as anxiety and insomnia. Acute withdrawal usually peaks around two weeks after stopping clonazepam and may last anywhere from a week to a month, according to information published in the Center for Substance Abuse Treatment’s Substance Abuse Treatment Advisory. The bulk of the withdrawal side effects will likely occur during acute withdrawal. Protracted withdrawal may include a continuation of psychological symptoms and drug cravings that may appear without warning at any time for several months or even years after the cessation of Klonopin. Not everyone will experience all three phases of withdrawal as addiction and withdrawal are unique to each individual. For instance, protracted withdrawal is considered fairly rare; however, it may be more likely to occur in someone taking clonazepam than someone taking a shorter-acting benzo such as alprazolam (Xanax). Protracted withdrawal may be able to be avoided or controlled with therapy and mental health treatment. Treating Clonazepam Withdrawal Safely AS WITH ANY BENZODIAZEPINE, MEDICAL DETOX IS NECESSARY FOR THOSE WITHDRAWING FROM CLONAZEPAM.
Recommended publications
  • Benzodiazepines
    Benzodiazepines Using benzodiazepines in Children and Adolescents Overview Benzodiazepines are group of medications used to treat several different conditions. Some examples of these medications include: lorazepam (Ativan®); clonazepam (Rivotril®); alprazolam (Xanax®) and oxazepam (Serax®). Other benzodiazepine medications are available, but are less commonly used in children and adolescents. What are benzodiazepines used for? Benzodiazepines may be used for the following conditions: • anxiety disorders: generalized anxiety disorder; social anxiety disorder; post-traumatic stress disorder (PTSD); panic attacks/disorder; excessive anxiety prior to surgery • sleep disorders: trouble sleeping (insomnia); waking up suddenly with great fear (night terrors); sleepwalking • seizure disorders (epilepsy) • alcohol withdrawal • treatment of periods of extreme slowing or excessive purposeless motor activity (catatonia) Your doctor may be using this medication for another reason. If you are unclear why this medication is being prescribed, please ask your doctor. How do benzodiazepines work? Benzodiazepines works by affecting the activity of the brain chemical (neurotransmitter) called GABA. By enhancing the action of GABA, benzodiazepines have a calming effect on parts of the brain that are too excitable. This in turn helps to manage anxiety, insomnia, and seizure disorders. How well do benzodiazepines work in children and adolescents? When used to treat anxiety disorders, benzodiazepines decrease symptoms such as nervousness, fear, and excessive worrying. Benzodiazepines may also help with the physical symptoms of anxiety, including fast or strong heart beat, trouble breathing, dizziness, shakiness, sweating, and restlessness. Typically, benzodiazepines are prescribed to manage anxiety symptoms that are uncomfortable, frightening or interfere with daily activities for a short period of time before conventional anti-anxiety treatments like cognitive-behavioural therapy or anti-anxiety takes effect.
    [Show full text]
  • The Effect of Opioids on Emotional Reactivity
    The Effect of Opioids on Emotional Reactivity Steven M. Savvas, BHSc (Hons) Discipline of Pharmacology, School of Medical Sciences, Faculty of Health Sciences University of Adelaide August, 2013 A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy i Steven M. Savvas, PhD Thesis, 2013 TABLE OF CONTENTS Abstract .................................................................................................................................... xi Declaration ............................................................................................................................ xiii Acknowledgements ............................................................................................................... xiv CHAPTER 1 - INTRODUCTION ...................................................................................... 1 1.1 OPIOIDS AND OPIOID MAINTENANCE TREATMENT ...................................... 1 1.1.1 A BRIEF HISTORY OF OPIOIDS .......................................................................... 1 1.1.2 OPIOID RECEPTORS ............................................................................................ 1 1.1.3 ADAPTATION TO OPIOIDS.................................................................................. 3 1.1.3.1 Tolerance ........................................................................................................ 4 1.1.3.2 Withdrawal ...................................................................................................... 4 1.1.3.3 Dependence
    [Show full text]
  • Module II Opioids
    Module II Opioids 101 Module II: Opioids 101 Module II is designed to introduce participants to basic facts about opioids, including information on pharmacology, acute and long-term effects, and basic information about treatments for opioid addiction. This module contains background information necessary to understand the role of buprenorphine in the opioid treatment system. If the audience is already highly knowledgeable about opioid treatment, this module should be abbreviated or omitted. Slide 1: Title Slide Slide 1 The next module provides an overview of opioids and opioid treatment, setting the stage to see the role of buprenorphine in the treatment system. Slide 2: Goals for Module II Slide 2 We are now going to turn a little more directly to the issue of opioid addiction. This module reviews the following: Opioid addiction and the brain Descriptions and definitions of opioid agonists, partial agonists and antagonists Receptor pharmacology Opioid treatment options Page 62 Buprenorphine Treatment: A Training for Multidisciplinary Addiction Professionals Slide 3: Opiate/Opioid: What’s the Difference? Slide 3 Throughout this training we are using the term opioid to define the class of drug with which we are dealing. It is important to understand what this term means. Opiate refers only to drugs or medications that are derived directly from the opium poppy. Examples include heroin, morphine, and codeine. Opioid is a broader term referring to opiates and other synthetically-derived drugs or medications that operate on the opioid receptor system and produce effects similar to morphine. Examples include methadone, buprenorphine, meperidine, and fentanyl. Note to the Trainer(s): All opiates are opioids, but not all opioids are opiates.
    [Show full text]
  • ED325463.Pdf
    DOCUMENT RESUME ED 325 463 SP 032 697 AUTHOR McCorry, Frank T.T.TLE Preventing Substance kbuse: A Comprehensive Program for Catholic Educators. INSTITUTION National Catholic Educational Association, Washington, DC. Dept. of Elementary Schools. REPORT NO ISBN-1-55833-040-2 PUB DATE 90 NOTE 116p. AVAILABLE FROMNational Catholic Educational Association, Suite 100, 1077 30th St., NW, Washington, DC 20007-3852 ($8.70). PUD TYPE Guides - Non-Classroom Use (055) EDRS PRICE MF01/PC05 Plus Postage. DESCRIPTORS Alcohol AbIlse; *Catholic Educators; *Catholic Schools; *Drug Education; Elementary Secondary Education; Intervention; Parent Role; Prevention; Program Development; Referral; *Substance Abuse; *Teacher Role ABSTRACT This book provides information for teachers about drugs are their effects on body and mind, and explains the role of teachTrs in effective drug education, prevention, and ass:stance programs. Suggestions on preventing drug abuse are also directed to the Catholic community and parents, along with a challenge to introduce programs on the local, regional, and national levels. The book is comprised of 10 chapters: (1) "Understanding the Problem"; (2) "Gateway Drugs: The Beginning of the Problem"; (3) "Cocaine, Crack, Designer Drugs";(4) "Prevention and the 'Prevention, Intervention, Education, and Referral' (PIER) Program";(F) "Education--The Foundation of PIER"; (6) "Prevention--Working with Students";(7) "Intervention and Refel-ral--Timely Help";(8) "The Teacher as Healer"; (9) "PIER--How to Implement :t"; and (10) "The Five Knows
    [Show full text]
  • Prescription Drug Abuse See Page 10
    Preventing and recognizing prescription drug abuse See page 10. from the director: The nonmedical use and abuse of prescription drugs is a serious public health problem in this country. Although most people take prescription medications responsibly, an estimated 52 million people (20 percent of those aged 12 and Prescription older) have used prescription drugs for nonmedical reasons at least once in their lifetimes. Young people are strongly represented in this group. In fact, the National Institute on Drug Abuse’s (NIDA) Drug Abuse Monitoring the Future (MTF) survey found that about 1 in 12 high school seniors reported past-year nonmedical use of the prescription pain reliever Vicodin in 2010, and 1 in 20 reported abusing OxyContin—making these medications among the most commonly abused drugs by adolescents. The abuse of certain prescription drugs— opioids, central nervous system (CNS) depressants, and stimulants—can lead to a variety of adverse health effects, including addiction. Among those who reported past-year nonmedical use of a prescription drug, nearly 14 percent met criteria for abuse of or dependence on it. The reasons for the high prevalence of prescription drug abuse vary by age, gender, and other factors, but likely include greater availability. What is The number of prescriptions for some of these medications has increased prescription dramatically since the early 1990s (see figures, page 2). Moreover, a consumer culture amenable to “taking a pill for drug abuse? what ails you” and the perception of 1 prescription drugs as less harmful than rescription drug abuse is the use of a medication without illicit drugs are other likely contributors a prescription, in a way other than as prescribed, or for to the problem.
    [Show full text]
  • Similitude and Rebound Effect of Drugs
    son, that its exact opposite, when, as has been observed, there is actually such a thing, is produced in the secondary action Similitude and Rebound by our vital force”. Effect of Drugs (Organon of Medicine, paragraph 65) Based on this postulate or “natural law”, homeopathy makes use of the secondary Scientific Evidence and action of the organism as a therapeutic reaction, and prescribes to ill individuals Therapeutic Application medicines that cause symptoms similar to the disorders they themselves cause (prin- ciple of therapeutic similitude), thus stimu- Marcus Zulian Teixeira, Brazil lating the organism to react against its own disease. In Ancient Greece, Hippocrates classically moted alterations in the different systems taught that there were two approaches to of the human body, and the following sec- Although little was divulged by modern PHILOSOPHY AND DISCUSSION the treatment of disease, namely the princi- ondary action of the organism (vital reaction pharmacology, since it opposes convention- ple of contraries and the principle of simi- or conservation force). The latter acts by al treatment, this same secondary action or lars. Treatment according to the principle neutralising the primary disorders caused homeostatic reaction of the organism has of contraries employs drugs that act con- by drugs, in an attempt to maintain the bal- been observed with the use of several types trary to or by palliating (“anti-”)thesymp- ance of the internal milieu or homeostasis: of modern palliative (antipathic or enantio- toms of the disease (e.g., anti-inflammato- pathic) drugs as a rebound effect or para- ries, antacids, antidepressants, etc.). This is “[…] Excessive vivacity follows the use of doxical reaction of the organism.Wehave the main approach to treatment applied by strong coffee (primary action), but slug- been systematically studying for the last fif- conventional medicine, also known as “al- gishness and drowsiness remain for a long teen years the rebound effect of modern lopathy”.
    [Show full text]
  • Withdrawal Are Important in the CSA 8-Factor Analysis to Inform Drug Scheduling Recommendations
    Jack E. Henningfield, Ph.D. Vice President, Research, Health Policy and Abuse Liability Pinney Associates And Professor, Adjunct, Behavioral Biology Department of Psychiatry and Behavioral Sciences The Johns Hopkins University School of Medicine Presented at ASAM, April 9, 2017, from 8:30-10:00 am at the Grand Salon A, In the Symposium: Evaluating Drug Dependence: Regulatory, Methodological and Clinical Challenges. New Orleans Hilton Riverside 1 PinneyAssociates.com Through PinneyAssociates, I provide consulting services on the development and regulation of pharmaceutical products and electronic nicotine delivery systems for which development goals may include reduced abuse potential. This includes abuse potential assessment and abuse-deterrent drug formulation evaluation to inform scheduling and abuse-deterrent labeling recommendations. 2 PinneyAssociates.com Parallels with one of the 20th century’s top 10 public health advances: Cars made with better materials and designs, and safeguards to protect passengers, better education, and with regulatory standards and oversights that incentivizes advances by industry 3 PinneyAssociates.com 1. Developing medicines with lower risks of abuse and physical dependence – a shared goal of FDA, public health, and pharmaceutical companies 2. Goals and challenges for new medications development 3. Definitions and why they matter 4. Clinical trials: At the intersection of research and clinical practice: A critical but challenging opportunity to characterize the abuse and physical dependence potential of new medicines 5. The Controlled Substances Act (CSA) 8 Factors to guide drug scheduling recommendations by FDA, NIDA and DEA 4 PinneyAssociates.com 1. FDA incentivized pharma with the potential for less restrictive scheduling and abuse deterrent labeling for opioids – but it needs science to get it right 2.
    [Show full text]
  • 2020 Alcohol and Other Drug (AOD) – Annual Notification
    Salve Regina University 2020 Alcohol and Other Drug (AOD) – Annual Notification 1 INTRODUCTION This report is distributed annually in compliance with The Drug-Free Schools and Campuses Act of 1989. Part 86, the Drug-Free Schools and Campuses Regulations, requires that, as a condition of receiving funds or any other form of financial assistance under any federal program, an Institution of Higher Education (IHE) must certify that it has adopted and implemented a program to prevent the unlawful possession, use, or distribution of illicit drugs and alcohol by students and employees. Salve Regina University, as an institution of higher learning, exists to enhance the mental, physical, and spiritual development of each and every member of its community. Substance abuse is at odds with the basic purposes of any learning environment. The University remains dedicated to the reduction and elimination of substance abuse within the University community. STANDARDS OF CONDUCT It is the policy of Salve Regina University to strive to maintain a secure work environment that is free from the effects of students and employees under the influence of unlawful drugs or abuse of alcoholic beverages. EMPLOYEES Alcoholic beverages may only be consumed by those persons over the age of 21. Employees are expected to comply with state law regarding the consumption and possession of alcoholic beverages and to exercise good judgment when using alcoholic beverages. Alcohol use or possession on University property is not permitted except at officially sanctioned University functions. It is illegal to manufacture, distribute, dispense, possess, or use controlled substances on University property. For more information on employee standards of conduct, please refer to the University’s “Employee Alcohol Use” policy at https://portal.salve.edu/mysalveinfo/officesservices/humanresources/_layouts/15/WopiFrame.aspx?sourcedoc =/mysalveinfo/officesservices/humanresources/Policies/Employee%20Alcohol%20Use.pdf&action=default STUDENTS The University is committed to maintaining high standards of behavior.
    [Show full text]
  • Rebound Phenomenon – Important and Ubiquitous in Pharmacotherapy
    Review article UDC: 615.015.4:615.2 doi:10.5633/amm.2018.0420 REBOUND PHENOMENON – IMPORTANT AND UBIQUITOUS IN PHARMACOTHERAPY Maja Koraćević1, Jelena Lalić1, Sonja Nedeljković2, Goran Koraćević3,4 The rebound effect represents a common characteristic of the numerous classes of modern drugs and can result in serious and even fatal disorders. For example, prolonged admi- nistration of proton pump inhibitor (PPI) leads to moderate hypergastrinemia in 20-25%. This hypergastrinemia will result in rebound gastric acid hypersecretion in 30-40% of patients following the abrupt PPI discontinuation. PPIs are among the most widely used drugs worldwide. An abrupt cessation of chronic corticosteroid, beta blocker, or opioid treatment may also provoke rebound phenomenon. Even in heart failure patients, beta blocker withdrawal on admission resulted in a significant increase of the probability of in-hospital mortality. The inci- dence of a rebound phenomenon depends on numerous factors, including the intensity and duration of action of a particular drug and how long it has been applied; the susceptibility of an individual patient (regarding the comorbidities and the severity of the primary disease) and the related circumstances (e.g, co-therapy). The clinical importance of the rebound phenomenon varies from academic to lethal. Even rare rebounds found for some classes of drugs are becoming very important if the drug has been used often globally. Acta Medica Medianae 2018;57(4):148-152. Key words: rebound, proton pump inhibitor, corticosteroid, beta blocker, opioid 1University of Niš, Faculty of Medicine, Department of sudden withdrawal of an efficacious medicament will Pharmacy, Niš, Serbia allow the stimulant to act on increased number of 2Pharmacy “Nevenpharm”, Niš, Serbia 3University of Niš, Faculty of Medicine, Niš, Serbia receptors on target cells, resulting in the rebound of 4Department for Cardiovascular Diseases, Clinical Center Niš, symptoms and signs of the disease.
    [Show full text]
  • Current Concepts on Drug Abuse and Dependence Daniela Luiza Baconi Carol Davila University of Medicine and Pharmacy, Daniela [email protected]
    Journal of Mind and Medical Sciences Volume 2 | Issue 1 Article 4 2015 Current Concepts on Drug Abuse and Dependence Daniela Luiza Baconi Carol Davila University of Medicine and Pharmacy, [email protected] Anne-Marie Ciobanu Carol Davila University of Pharmacy and Medicine Ana Maria Vlăsceanu Carol Davila University of Medicine and Pharmacy Oana Denisa Cobani St. John Emergency Hospital Carolina Negrei Carol Davila University of Medicine and Pharmacy See next page for additional authors Follow this and additional works at: http://scholar.valpo.edu/jmms Part of the Medicine and Health Sciences Commons Recommended Citation Baconi, Daniela Luiza; Ciobanu, Anne-Marie; Vlăsceanu, Ana Maria; Cobani, Oana Denisa; Negrei, Carolina; and Bălălău, Cristian (2015) "Current Concepts on Drug Abuse and Dependence," Journal of Mind and Medical Sciences: Vol. 2 : Iss. 1 , Article 4. Available at: http://scholar.valpo.edu/jmms/vol2/iss1/4 This Review Article is brought to you for free and open access by ValpoScholar. It has been accepted for inclusion in Journal of Mind and Medical Sciences by an authorized administrator of ValpoScholar. For more information, please contact a ValpoScholar staff member at [email protected]. Current Concepts on Drug Abuse and Dependence Authors Daniela Luiza Baconi, Anne-Marie Ciobanu, Ana Maria Vlăsceanu, Oana Denisa Cobani, Carolina Negrei, and Cristian Bălălău This review article is available in Journal of Mind and Medical Sciences: http://scholar.valpo.edu/jmms/vol2/iss1/4 JMMS 2015, 2(1): 18- 33. REVIEW Current concepts on drug abuse and dependence Daniela Luiza Baconi1, Anne-Marie Ciobanu2, Ana Maria Vlăsceanu1, Oana Denisa Cobani3, Carolina Negrei1, Cristian Bălălău4 1 Carol Davila University of Medicine and Pharmacy, Faculty of Pharmacy, Department of Toxicology 2 Carol Davila University of Medicine and Pharmacy, Faculty of Pharmacy, Medicines Control 3 St.
    [Show full text]
  • Rsat-Tta.Com/Home Stephen Keller RSAT TTA Coordinator [email protected]
    RESIDENTIAL SUBSTANCE ABUSE TREATMENT (RSAT) Detoxification vs. Withdrawal Management: The Jail Challenge June 19, 2019 Dr. Andy Klein Advocates for Human Potential, Inc. This project was supported by grant No. 2016-MU-BX-K021 awarded by the Bureau of Justice Assistance. The Bureau of Justice Assistance is a component of the Office of Justice Programs, which also includes the Bureau of Justice Statistics, the National Institute of Justice, the Office of Juvenile Justice and Delinquency Prevention, the SMART Office, and the Office for Victims of Crime. Point of view or opinions in this document are those of the author and do not represent the official position or policies of the United States Department of Justice. Housekeeping: Functions 2 Housekeeping: Communication 3 Dr. Andy Klein Project Director, RSAT-TTA Senior Scientist for Criminal Justice Advocates for Human Potential, Inc. 4 Learning Objectives: • Identify the challenges jails and prisons face with increased incarcerated individuals suffering from withdrawal • Describe treatment options for individuals with SUD’s in corrections facilities • Understand and be able to implement necessary protocols to properly treat incarcerated individuals in need of detoxification services 5 Opioid Detox (2016) 3000000 2500000 2000000 1500000 1000000 500000 0 jail residential rehab hospital Detoxification Opioids: (severe physical withdrawal symptoms) Alcohol: (severe physical withdrawal symptoms) Benzodiazepines: (severe physical withdrawal symptoms) Barbituates: (severe physical withdrawal symptoms) Methamphetamine (crystal meth): (severe physical withdrawal symptoms) Cocaine (mostly psychological withdrawal symptoms) Opioid Withdrawal Syndrome DSM-5 Criteria: A. Either: 1) Cessation of (or reduction in) opioid use that has been heavy and prolonged (several weeks or longer), or 2) administration of an opioid antagonist after a period of opioid use B.
    [Show full text]
  • B.A./B.Com./BCA/BBA Part-I Drug Abuse : Problem, Management
    B.A./B.Com./BCA/BBA PartI Drug Abuse : Problem, Management SemesterII and Prevention Lesson No. 1.1 Author : Dr. Richa Shri Concept and overview Contents : • What are drugs? • What is drug abuse? • Prevalence of the menace of drug abuse • Difference between drug abuse, drug dependence and drug addiction • Physical and psychological dependence-concept of drug tolerance B.A./B.Com./BCA/BBA Part-I (Semester-II) 2 Drug Abuse : Problem, Management and Prevention B.A./B.Com./BCA/BBA Part-I (Semester-II) 3 Drug Abuse : Problem, Management and Prevention B.A./B.Com./BCA/BBA Part-I (Semester-II) 4 Drug Abuse : Problem, Management and Prevention B.A./B.Com./BCA/BBA Part-I (Semester-II) 5 Drug Abuse : Problem, Management and Prevention What is a Drug? • A chemical substance used in the treatment, prevention or diagnosis of disease or used to otherwise enhance physical or mental well-being. • Any substance recognized in the official pharmacopoeia or formulary of the nation. • Any substance intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans or other animals. • Any article, other than food, intended to affect the structure or any function of the body of humans or other animals. • Any substance intended for use as a component of such a drug, but not a device or a part of a device. • A habit-forming medicinal or illicit substance, especially a narcotic. Drug In the broadest terms, a drug is “any substance which changes the way the body functions, mentally, physically or emotionally”. This definition does not discriminate between: ❖ Alcohol ❖ Tobacco ❖ Caffeine ❖ Solvents ❖ Over The Counter Drugs ❖ Prescribed Drugs ❖ Illicit drugs The use of a chemical, legal or illegal, which causes significant impairment in: • physical functioning • mental functioning • emotional functioning • social functioning “Substance use disorder” is a preferred term in the scientific community.
    [Show full text]